To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis

A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter, Dose-finding, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of ALC-2203 in Patients with Acute Bronchitis

Inclusion Criteria:

1. Male and female participants aged 19 years or older.

2. Patients diagnosed with acute bronchitis with:

   • A Bronchitis Severity Score (BSS) of ≥ 5 at Visit 2.
   • A sputum subscore of at least 1 at Visit 2.

3. Onset of acute bronchitis symptoms within 48 hours prior to Visit 2.

4. Patients who voluntarily agree to participate

Exclusion Criteria:

1. Patients who, in the opinion of the investigator, have severe respiratory diseases such as allergic asthma, chronic bronchitis, or asthma
2. Patients who are currently taking, or are expected to take during the study period, antitussive or expectorant medications containing agents such as codeine or dextromethorphan
3. Patients who have participated in another clinical trial within 4 weeks prior to screening